<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2716">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421664</url>
  </required_header>
  <id_info>
    <org_study_id>2020-6549</org_study_id>
    <nct_id>NCT04421664</nct_id>
  </id_info>
  <brief_title>Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)</brief_title>
  <official_title>Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Objective:

      To test if early preemptive hydroxychloroquine therapy can prevent disease progression in
      persons with known symptomatic COVID-19 disease, decreasing hospitalizations and symptom
      severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral
      infection causing COVID19. Therapy is generally not given to persons who are not
      hospitalized.

      Hydroxychloroquine may have antiviral effects against SARS-CoV2 which may decrease disease
      severity when given early. This trial will use a modification of standard malaria dosing of
      hydroxychloroquine to provide preemptive therapy for those with early symptoms.

      This study is a continuation of NCT04308668 which looked at post-exposure prophylaxis (now
      closed) and early treatment in the USA (now closed, data to be pooled) and Canada (which
      continues in this study). On April 28, 2020 NCT04308668 changed its primary outcome to
      symptomatic improvement in the preemptive therapy arm. This study continues enrollment for
      the primary ordinal outcome of hospitalization; hospitalization with intensive care stay; or
      death.

      People in the participating Canadian provinces can help answer this critically important
      question. No in-person visits are needed.

      The doses of hydroxychloroquine being used have been approved by Health Canada.

      This trial is targeting the following groups of people:

      If you are symptomatic with a positive COVID-19 test within the first 4 days of symptoms and
      are not hospitalized; OR If you have had occupational exposure with known exposure to someone
      with lab-confirmed COVID-19 within the last 14 days AND have compatible symptoms starting
      within the last 4 days;

      You may participate if you live anywhere in the Canadian Provinces of Quebec, Manitoba,
      Alberta, British Columbia, Newfoundland or Ontario.

      For information on how to participate in the research trial, go to:

      www.covid-19research.ca
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Request of Health Canada after publication of https://doi.org/10.7326/M20-4207
  </why_stopped>
  <start_date type="Actual">March 25, 2020</start_date>
  <completion_date type="Actual">August 17, 2020</completion_date>
  <primary_completion_date type="Actual">August 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ordinal Scale of COVID19 Disease Severity at 14 days</measure>
    <time_frame>14 days</time_frame>
    <description>Participants will self-report disease severity status as one of the following 3 options; no COVID19 illness (score of 1), COVID19 illness with no hospitalization (score of 2), or COVID19 illness with hospitalization or death (score of 3). Increased scale score indicates greater disease severity. Outcome is reported as the percent of participants who fall into each category per arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospitalization</measure>
    <time_frame>14 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who require hospitalization for COVID19-related disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 related Death</measure>
    <time_frame>90 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all-cause Death</measure>
    <time_frame>90 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who expire due to all causes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-Cause Study Medicine Discontinuation or Withdrawal</measure>
    <time_frame>14 days</time_frame>
    <description>Outcome reported as the number of participants in each arm who discontinue or withdraw medication use for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall symptom severity at 5 and 14 days</measure>
    <time_frame>5 and 14 days</time_frame>
    <description>Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall change in disease severity over 14 days among those who are symptomatic at baseline</measure>
    <time_frame>14 days</time_frame>
    <description>Repeated Measure mixed regression model of change in: Visual Analog Scale 0-10 score of rating overall symptom severity (0 = no symptoms; 10 = most severe)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Corona Virus Infection</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive the study drug, hydroxychloroquine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive a placebo treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18 years of age or older AND provision of informed consent

        WITH

        Symptomatic COVID-19 disease with confirmed diagnosis with PCR+ SARS-CoV-2 within &lt;= 4 days
        of symptoms

        OR

        Healthcare worker with compatible symptoms with exposure to known PCR+ case &lt;= 14 days (and
        no available/pending testing for the individual).

        Exclusion Criteria:

          -  Current hospitalization

          -  Allergy to chloroquine or hydroxychloroquine

          -  Severe diarrhea and/or vomiting

          -  Significant hepatic impairment defined as known cirrhosis with history of hepatic
             encephalopathy or ascites.

          -  Prior retinal eye disease

          -  Concurrent malignancy requiring chemotherapy

          -  Known Chronic Kidney disease, Stage 4 or 5 or dialysis.

          -  Known glucose-6 phosphate dehydrogenase (G6PD) deficiency.

          -  Known ventricular arrythmia, known prolonged QTc interval, or any known episode of
             sudden cardiac death

          -  Known Porphyria

          -  Weight &lt;40 kg

          -  Known Pregnancy of Breastfeeding

          -  Current use of chloroquine or hydroxychloroquine

          -  Current use of Artemether, Dapsone, Lumefantrine or Mefloquine

          -  Current use of Cardiac medicines: amiodarone, digoxin, dofetilide, flecainide,
             procainamide, sotalol, or propafenone

          -  Current use of the following antimicrobials: levofloxacin, ciprofloxacin,
             moxifloxacin, azithromycin, clarithromycin, erythromycin, ketoconazole, or
             itraconazole

          -  Current use of the following antidepressants: amitriptyline, citalopram, desipramine,
             escitalopram, imipramine, doxepin, fluoxetine, sertraline, bupropion (Wellbutrin), or
             venlafaxine

          -  Current use of the following antipsychotic or mood stabilizers: haloperidol,
             droperidol, lithium, quetiapine, thioridazine, ziprasidone

          -  Current use of methadone

          -  Current use of Sumatriptan, Zolmitriptan other than &quot;as needed&quot;

          -  Current use of systemic chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd C Lee, MD MPH FIDSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Health</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H4A3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 5, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>September 18, 2020</last_update_submitted>
  <last_update_submitted_qc>September 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Todd Lee</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Corona virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified dataset will be included with publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>At time of publication</ipd_time_frame>
    <ipd_access_criteria>To be publicly provided</ipd_access_criteria>
    <ipd_url>http://www.covid-19research.ca</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

